Abstract
High dose rate brachytherapy (HDR-BT) is one of the many modalities for prostate cancer treatment. Due to the nature of HDR-BT, in vivo dosimetry is feasible and can be used to verify consistent dose delivery. In order to validate a dose verification system for HDR-BT prostate cancer treatment, a radiophotoluminescent glass dosimeter (RPLGD) was used and the measurements were compared with those from a thermoluminescent dosimeter. The RPLGD shows many advantages in HDR-BT dose measurement, such as repeatability, stability, and small effective size. These advantages make the RPLGD a superior option for use as a dosimeter in HDR-BT. The results described here show that the difference between the measured dose and the treatment planned dose is less than 5%. A Monte Carlo simulation for the dose was performed using Monte Carlo N -particle to investigate position error. This study concludes that the RPLGD is a promising and reliable dosimeter for HDR-BT in vivo dosimetry with clinically acceptable accuracy.
Original language | English |
---|---|
Pages (from-to) | 5558-5564 |
Number of pages | 7 |
Journal | Medical Physics |
Volume | 35 |
Issue number | 12 |
DOIs | |
State | Published - 2008 |
Externally published | Yes |
Keywords
- High dose rate brachytherapy
- Monte Carlo N-particle code
- Prostate cancer
- Radiophotoluminescent glass dosimeter